X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
greater-than-or-equal-to-70 years (26) 26
aged (25) 25
humans (25) 25
index medicus (25) 25
oncology (17) 17
age factors (16) 16
female (16) 16
aged, 80 and over (13) 13
retrospective studies (13) 13
age (12) 12
cancer (12) 12
male (12) 12
middle aged (12) 12
treatment outcome (12) 12
chemotherapy (11) 11
survival (9) 9
obstetrics & gynecology (8) 8
survival rate (8) 8
analysis (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
disease-free survival (7) 7
elderly (7) 7
hematology, oncology and palliative medicine (7) 7
ovarian cancer (7) 7
comprehensive geriatric assessment (6) 6
neoplasm staging (6) 6
prostate cancer (6) 6
adult (5) 5
aged patients (5) 5
carcinoma (5) 5
care and treatment (5) 5
comorbidity (5) 5
endometrial cancer (5) 5
multiple myeloma - therapy (5) 5
ovarian neoplasms - drug therapy (5) 5
prostatic neoplasms - surgery (5) 5
quality-of-life (5) 5
surgery (5) 5
therapy (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
chemotherapy, adjuvant (4) 4
combined modality therapy (4) 4
diagnosis (4) 4
endometrial neoplasms - pathology (4) 4
geriatric assessment (4) 4
geriatrics (4) 4
hematology (4) 4
men (4) 4
mortality (4) 4
multiple myeloma (4) 4
multivariate analysis (4) 4
older (4) 4
paclitaxel (4) 4
perioperative morbidity (4) 4
phase-ii (4) 4
prostatic neoplasms - mortality (4) 4
prostatic neoplasms - pathology (4) 4
radical prostatectomy (4) 4
urology & nephrology (4) 4
women (4) 4
advanced ovarian-cancer (3) 3
age contrasts (3) 3
aged greater-than-or-equal-to-70 years (3) 3
breast-cancer (3) 3
carboplatin (3) 3
elderly patients (3) 3
elderly-men (3) 3
elderly-patients (3) 3
epithelial ovarian-cancer (3) 3
hematopoietic stem cells (3) 3
impact (3) 3
medical research (3) 3
morbidity (3) 3
neoplasm grading (3) 3
older men (3) 3
older women (3) 3
paclitaxel - administration & dosage (3) 3
patient outcomes (3) 3
prostatectomy (3) 3
prostatic neoplasms - therapy (3) 3
relapse (3) 3
risk factors (3) 3
transplantation (3) 3
transplantation, autologous (3) 3
treatment (3) 3
urology (3) 3
adenocarcinoma, clear cell - mortality (2) 2
adenocarcinoma, clear cell - pathology (2) 2
adjuvant treatment (2) 2
autografts (2) 2
blood (2) 2
carboplatin - administration & dosage (2) 2
carboplatin - adverse effects (2) 2
carcinoma - pathology (2) 2
carcinoma - surgery (2) 2
carcinoma, ovarian epithelial (2) 2
chemotherapy toxicity (2) 2
clinical trials as topic (2) 2
clinical-trials (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 01/2011, Volume 29, Issue 2, pp. 235 - 241
Purpose Older men are more likely to be diagnosed with high-risk prostate cancer and to have lower overall survival. As a result, age often plays a role in... 
ANDROGEN-DEPRIVATION THERAPY | UNITED-STATES | MORTALITY | MANAGEMENT | ONCOLOGY | PREOPERATIVE NOMOGRAM | RISK | RADICAL PROSTATECTOMY | OLDER MEN | ELDERLY-MEN | GREATER-THAN-OR-EQUAL-TO-70 YEARS | Age Factors | Humans | Middle Aged | Logistic Models | Male | Survival Rate | Treatment Outcome | Aged | Prostatic Neoplasms - diagnosis | Prostatic Neoplasms - therapy | Index Medicus | Original Reports | Guc1 | Guc2
Journal Article
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 137, Issue 3, pp. 401 - 405
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2011, Volume 22, Issue 11, pp. 2417 - 2423
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2017, Volume 146, Issue 2, pp. 268 - 272
Highlights • There was no difference in OS or PFS between older and younger women receiving IP. • The IP regimen caused a higher incidence of neutropenia in... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | INTRAVENOUS CISPLATIN | PROGNOSTIC-FACTOR | GYNECOLOGIC-ONCOLOGY-GROUP | STAGE-III OVARIAN | ONCOLOGY | PHASE-III | QUALITY-OF-LIFE | EPITHELIAL OVARIAN-CANCER | GREATER-THAN-OR-EQUAL-TO-70 YEARS | AGE | PACLITAXEL | OBSTETRICS & GYNECOLOGY | Age Factors | Adenocarcinoma, Clear Cell - mortality | Humans | Ovarian Neoplasms - pathology | Ovarian Neoplasms - mortality | Cytoreduction Surgical Procedures | Neoplasms, Glandular and Epithelial - mortality | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Retrospective Studies | Chemotherapy, Adjuvant | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - pathology | Neoplasms, Cystic, Mucinous, and Serous - pathology | Bevacizumab - administration & dosage | Infusions, Parenteral | Survival Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Endometrioid - mortality | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Adenocarcinoma, Clear Cell - pathology | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Carcinoma, Endometrioid - pathology | Neoplasms, Cystic, Mucinous, and Serous - mortality | Adenocarcinoma, Clear Cell - drug therapy | Chemotherapy | Analysis | Cancer | Medicine, Experimental | Medical research | Ovarian cancer | Index Medicus
Journal Article
Lung Cancer, ISSN 0169-5002, 2012, Volume 77, Issue 1, pp. 97 - 103
Journal Article
Internal Medicine, ISSN 0918-2918, 2013, Volume 52, Issue 1, pp. 63 - 70
Objective The feasibility and efficacy of high-dose melphalan (HD-MEL) followed by autologous hematopoietic stem cell transplantation (auto-SCT) in elderly... 
autologous hematopoietic stem cell transplantation | elderly patients with multiple myeloma | high-dose melphalan | Elderly patients with multiple myeloma | High-dose melphalan | Autologous hematopoietic stem cell transplantation | SURVIVAL | SINGLE | METAANALYSIS | THALIDOMIDE | CHEMOTHERAPY | TRIAL | MEDICINE, GENERAL & INTERNAL | HIGH-DOSE THERAPY | MELPHALAN | GREATER-THAN-OR-EQUAL-TO-70 YEARS | AGE | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Reference Values | Transplantation, Autologous | Case-Control Studies | Feasibility Studies | Multiple Myeloma - therapy | Statistics, Nonparametric | Vincristine - administration & dosage | Female | Retrospective Studies | Severity of Illness Index | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Risk Assessment | Graft Survival | Survival Rate | Treatment Outcome | Combined Modality Therapy | Chi-Square Distribution | Cytarabine - administration & dosage | Disease-Free Survival | Graft Rejection | Aged | Hematopoietic Stem Cell Transplantation - methods | Index Medicus | Autografts | Dexamethasone | stem cell transplantation | Multiple myeloma | Doxorubicin | Survival | Vincristine | Infection | Chemotherapy | Cyclophosphamide | Melphalan | Peripheral blood | Geriatrics
Journal Article
Oncology, ISSN 0030-2414, 10/2013, Volume 85, Issue 3, pp. 168 - 172
Journal Article